Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daiichi Sankyo
Biotech
Merck and Daiichi pull lung cancer filing after FDA pushback
Daiichi and Merck withdrew an ADC filing after the FDA said they lacked the data for accelerated approval in a lung cancer population.
Nick Paul Taylor
Sep 28, 2026 4:30am
GSK’s ADC lays down marker for lung cancer scrap with Merck
Sep 12, 2026 7:00pm
Vivace adds new CEO, CBO ahead of ph. 3 trial—Chutes & Ladders
Aug 28, 2026 8:30am
Eli Lilly takes top spot on new biopharma productivity ranking
Jul 28, 2026 1:00pm
How Daiichi Sankyo plans to stay ahead in the ADC game
Jun 17, 2026 6:00pm
ASCO: BMS' bispecific ADC puts TROP2 drugs on notice
Jun 2, 2026 8:00am
